{
    "clinical_study": {
        "@rank": "131151", 
        "arm_group": [
            {
                "arm_group_label": "Nitrate rich beetroot juice", 
                "arm_group_type": "Active Comparator", 
                "description": "Control subjects will receive 280 mL of Nitrate-rich concentrated beetroot juice (containing 24 mmol of NO-3). Hypertensive subjects or subjects with heart failure (reduced ejection fraction or preserved ejection fraction) will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized."
            }, 
            {
                "arm_group_label": "Nitrate depleted beetroot juice", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control subjects will receive 280 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3). Hypertensive subjects or subjects with heart failure (reduced ejection fraction or preserved ejection fraction) will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized."
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective is to test the hypothesis that inorganic nitrate supplementation will:\n      (1) Improve exercise efficiency and performance; (2) Enhance the systemic vasodilator\n      reserve during exercise and specifically, the vasodilator response in exercising muscle; (3)\n      Reduce arterial wave reflections and arterial load; (4) Improve skeletal muscle\n      mitochondrial function. The investigators also hypothesize that the relative improvement in\n      exercise capacity will be larger in subjects with frank heart failure, who are nitric-oxide\n      deficient, compared to hypertensive and non-hypertensive subjects without heart failure."
        }, 
        "brief_title": "Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise Capacity", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Heart Failure With Normal Ejection Fraction", 
            "Heart Failure With Reduced Ejection Fraction", 
            "Hypertension", 
            "Subjects Free of Cardiovascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Heart Failure", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This represents a series of double-blind, controlled pilot randomized studies in which the\n      effects of nitrate-rich beetroot juice and nitrate-depleted beetroot juice will be assessed\n      in patients with heart failure and preserved ejection fraction (n=20), patients with heart\n      failure and reduced ejection fraction (n=20), normal volunteers (n=20), and patients with\n      hypertension (n=20). A total of 80 subjects will be enrolled over a 1.5 year period and\n      randomized in a cross-over design to a single dose of nitrate-rich beetroot juice and\n      nitrate-depleted beetroot juice. The order of the interventions will be randomized; thus,\n      all subjects will receive the nitrate-rich and nitrate-depleted juice, with a 4-7 day\n      washout period in-between studies."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The investigators will enroll 80 subjects >18 years of age who are either: (1)\n        Normotensive and have no evidence of heart failure; (2) Have hypertension (defined by\n        JNC-7 criteria) but no heart failure; (3) Have a diagnosis of heart failure with reduced\n        ejection fraction (<50%) by 2d echocardiography and, current New York Heart Association\n        Class II-IV symptoms; (4) Have a diagnosis of heart failure with a preserved ejection\n        fraction (>50%) by 2d echocardiography, with current New York Heart Association Class\n        II-IV symptoms.\n\n        In addition, subjects with heart failure must meet the following inclusion criteria:\n\n          1. Chronic treatment with a loop diuretic for control of HF symptoms.\n\n          2. If EF is normal, subjects must demonstrate elevated filling pressures as evidenced by\n             at least one of the following: a) left atrial enlargement (LAVI > 32 mL/m2); b) at\n             least stage II diastolic dysfunction; c) Documentation of elevated NT-pro BNP levels\n             or other natriuretic peptide marker (BNP, ANP) according to the laboratory and assay\n             upper limit of normal in the previous year.\n\n          3. Stable medical therapy as defined by: (I) No addition or removal of ACE, ARB,\n             beta-blockers, or calcium channel blockers (CCBs) for 30 days. (II) No change in\n             dosage of ACE, ARBs, beta-blockers or CCBs of more than 100% for 30 days. (III) No\n             change in diuretic dose for 10 days.\n\n        Exclusion Criteria:\n\n          1. Rhythm other than sinus rhythm (i.e., atrial fibrillation).\n\n          2. Neuromuscular, orthopedic or other non-cardiac condition that prevents patient from\n             exercising.\n\n          3. Valve disease (> mild aortic or mitral stenosis; > moderate aortic or mitral\n             regurgitation).\n\n          4. Hypertrophic cardiomyopathy.\n\n          5. Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid).\n\n          6. Pericardial disease.\n\n          7. Primary pulmonary arteriopathy.\n\n          8. Have experienced a myocardial infarction or unstable angina, or have undergone\n             percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass\n             grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at\n             the time of consent.\n\n          9. Other clinically important causes of dyspnea such as morbid obesity or significant\n             lung disease defined by clinical judgment or use of steroids or oxygen for lung\n             disease within the past 6 months.\n\n         10. Systolic blood pressure < 110 mmHg or > 180 mm Hg.\n\n         11. Diastolic blood pressure < 40 mmHg or > 100 mmHg.\n\n         12. Resting heart rate (HR) > 100 bpm.\n\n         13. Hemoglobin <10 g/dL.\n\n         14. Patients with known severe liver disease (AST > 3x normal, alkaline phosphatase or\n             bilirubin > 2x normal).\n\n         15. Patients with a clinically indicated stress test demonstrating significant ischemia\n             within a year of enrollment which was not followed by percutaneous or surgical\n             revascularization.\n\n         16. Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardanafil or\n             tadalafil.\n\n         17. Known allergies to beetroot or lemon juice.\n\n         18. Current use of organic nitrates or phosphodiesterase inhibitors.\n\n         19. Pregnancy. Although beetroot juice has not knows teratogenic effects, we feel that\n             not enough data exist in this regard. Therefore, all females patients of reproductive\n             age will be required to undergo a pregnancy test prior to enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919177", 
            "org_study_id": "01415"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nitrate rich beetroot juice", 
                "description": "Subjects will receive 280 mL or 140 mL of Nitrate-rich concentrated beetroot juice.", 
                "intervention_name": "Nitrate rich beetroot juice", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Beet It Stamina Sports shots"
            }, 
            {
                "arm_group_label": "Nitrate depleted beetroot juice", 
                "description": "Subjects will receive 280 mL or 140 mL of nitrate-depleted beetroot juice.", 
                "intervention_name": "Nitrate depleted beetroot juice", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Beet It nitrate extracted (depleted) placebo shots"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Heart Failure", 
            "Arterial hemodynamics", 
            "Exercise capacity", 
            "Mitochondrial oxidative capacity"
        ], 
        "lastchanged_date": "November 16, 2013", 
        "location": {
            "contact": {
                "email": "julio.chirinos@uphs.upenn.edu", 
                "last_name": "Julio A Chirinos, MD, PhD", 
                "phone": "215-200-7779"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Philadelphia Veterans Affairs Medical Center"
            }, 
            "investigator": {
                "last_name": "Julio A Chirinos, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Inorganic Nitrates on Arterial Hemodynamics and Exercise Capacity", 
        "overall_contact": {
            "email": "julio.chirinos@uphs.upenn.edu", 
            "last_name": "Julio A Chirinos, MD, PhD", 
            "phone": "215-200-7779"
        }, 
        "overall_official": {
            "affiliation": "Philadelphia VA Medical Center & University of Pennsylvania", 
            "last_name": "Julio A Chirinos, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will assess the relationship between total power output and total O2 consumption (VO2, assessed via expired gas analysis)  during a maximal-effort supine bicycle exercise test.", 
            "measure": "Change in Peak exercise efficiency during maximal effort supine-bicycle exercise and peak oxygen consumption (VO2) during a maximal effort supine-bicycle exercise test", 
            "safety_issue": "No", 
            "time_frame": "Baseline study, repeat study 4-7 days later"
        }, 
        "reference": [
            {
                "PMID": "12524257", 
                "citation": "American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77. Review. No abstract available. Erratum in: Am J Respir Crit Care Med. 2003 May 15;1451-2."
            }, 
            {
                "PMID": "21982360", 
                "citation": "Manetos C, Dimopoulos S, Tzanis G, Vakrou S, Tasoulis A, Kapelios C, Agapitou V, Ntalianis A, Terrovitis J, Nanas S. Skeletal muscle microcirculatory abnormalities are associated with exercise intolerance, ventilatory inefficiency, and impaired autonomic control in heart failure. J Heart Lung Transplant. 2011 Dec;30(12):1403-8. doi: 10.1016/j.healun.2011.08.020. Epub 2011 Oct 7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919177"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Philadelphia Veterans Affairs Medical Center", 
            "investigator_full_name": "Julio A.Chirinos", 
            "investigator_title": "Director of non-invasive imaging & Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Reflection wave magnitude will be assessed using arterial tonometry to arrive at the augmentation index. The data will also be processed using custom designed software for wave separation analysis to quantify the magnitude and timing of the reflected waves.", 
                "measure": "Change in Arterial wave reflection magnitude", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }, 
            {
                "measure": "Change in Peripheral vascular resistance, total arterial compliance and reflection magnitude during supine bicycle peak exercise", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }, 
            {
                "measure": "Change in lower extremity exercise vasodilator reserve (change in femoral vascular resistance between rest and maximal effort supine-bicycle exercise)", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }, 
            {
                "measure": "Change in lower extremity blood flow reserve (change in femoral artery blood flow between rest and maximal effort supine-bicycle exercise)", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }, 
            {
                "measure": "Change in submaximal exercise efficiency (O2 consumption per power output during submaximal exercise and standardized handgrip exercise)", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }, 
            {
                "description": "The investigators will assess the oxygen consumption recovery kinetics after moderate forearm exercise, using repeated cuff brachial artery occlusions and near-infrared spectroscopy.", 
                "measure": "Change in Skeletal Muscle Mitochondrial Oxidative Capacity", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }, 
            {
                "description": "The investigators will assess the post-ischemic vasodilatory response in the forearm using brachial artery pulsed wave Doppler interrogations before and after inflation of a brachial cuff at 200 mmHg for 5 minutes. The investigators will also assess forearm microvascular skeletal muscle flow with near-infrared spectroscopy and forearm skin microvascular flow using laser Doppler.", 
                "measure": "Change in post-ischemic vasodilatory response", 
                "safety_issue": "No", 
                "time_frame": "Baseline study, repeat study 4-7 days later"
            }
        ], 
        "source": "Philadelphia Veterans Affairs Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philadelphia Veterans Affairs Medical Center", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}